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Chakos et al., 2001) could include heterogeneous samples, in part due
to unclear or lax TRS deﬁnitions. Hence, they are less helpful when
searching for evidence based treatment recommendations for TRS
(Miyamoto et al., 2015). Another important factors that contribute to
this heterogeneity among studies are: dosage differences, investigator
bias combined with the difﬁculty of blinding clozapine treatment as-Keywords:
Treatment-resistant schizophrenia
Antipsychotic
Response
Efﬁcacy
Clozapine
ReviewSchizophrenia affects 1% of general population and one of its features
is the heterogeneity of response to treatment. 20–30% of individuals
with schizophrenia have treatment-resistant schizophrenia (TRS)
(Lieberman, 1999). Correctly identifying these patients could contribute
to reduce burden in patients themselves, in society and in economy. In
fact, TRS constitutes about 60–70% of schizophrenia's cost burden
(Kennedy et al., 2014).
TRS deﬁnition was coined by Kane and colleagues in 1988 (Kane et
al., 1988). In this groundbreaking trial, they demonstrated superiority
in response rate of clozapine over chlorpromazine (30% vs 4%) in well-
deﬁned cohort of patientswho did not respond to threewell document-
ed antipsychotic trials and one prospective trial with high doses of
haloperidol. After that, TRS and treatment response concepts have expe-
rienced several variations, as analyzed in the review by Suzuki and col-
leagues (Suzuki et al., 2012), underlining heterogeneity of deﬁnitions
and proposing consensus deﬁnition.stitut d'Investigació Biomèdica-
t Pau, Carrer Sant Antoni Maria
ns).
ppears in www.mresist.eu.signment, and the effect of prior antipsychotic treatment (Kane and
Correll, 2016).
We performed a systematic and critical review of current literature
about efﬁcacy of drugs in well-deﬁned TRS. We analyzed key aspects
of methodology and quality, deﬁnitions of resistance and response, efﬁ-
cacy variables (response rate and mean improvement) and safety out-
comes. Here, in this letter, our aim is to present our conclusions about
the antipsychotics efﬁcacy and the problems affecting the interpretation
of studies on TRS.
Double-blinded randomized trials (DBRT) on TRS were searched
by: 1. a systematic search in April 2015 by the following search
strategy: schizophrenia[Title]) AND (“ultra-resistant”[Title] OR
“treatment-refractory”[Title]) OR “treatment-resistant”[Title]) AND
“English”[Language]) from Scopus, PubMed and CINAHL (EBSCO)
databases, 2. manual search. We included only studies on treatment ef-
ﬁcacy in a clear-deﬁned TRS population according to criteria proposed
by Suzuki et al. (2012):
1. History of treatment failure with two or more antipsychotics with
different binding proﬁle, clearly documented or prospective
validation.
2. Requirement in dose and duration: each treatment with an antipsy-
chotic has continued for six consecutive weeks at chlorpromazine-
equivalent doses of ≥600 mg/day.
3. Requirement in rating scales: each treatment has resulted in a failure
deﬁnedwith both Clinical Global Impression (CGI) ≥4 and Functional
Assessment for Comprehensive Treatment of Schizophrenia (FACT-
Sz) ≤49 or Global Assessment of Functioning (GAF) ≤50 or Positive
and Negative Syndrome Scale (PANSS) ≥75/Brief Psychiatric Rating
Scale (BPRS) ≥45.
Table 1
Double blinded randomized trials about antipsychotic efﬁcacy in treatment-resistant schizophrenia.
Trial Study
description
Compared drugs (mg/d) Response
rate
Completion
rate
Improvement
of symptoms
from baseline
Commentaries
FGA vs FGA
Lal et al., 2006 (1) n = 31
15 weeks
ITT
Inpatients
Levomepromazine
(810)/chlorpromazine (760)
53%/42% 90%/73% −10/−7 – No differences in efﬁcacy.
– Industry sponsored.
SGA vs FGA
Kane et al., 2007 (2) n = 300
6 weeks
PP
Aripiprazole (30)/perphenazine
(40)
27%/25% 71%/79% −10/−10 – No differences in efﬁcacy.
– Missing 116 patients between open-trial and
BRDT.
– TRS deﬁnition was incomplete.
– Industry sponsored.
Kane et al., 2006 (3) n = 306
12 weeks
ITT
Ziprasidone (155)/chlorpromazine
(740)
58%/55% 90%/88% NR – No differences in efﬁcacy.
– Unclear results, not reported baseline severity.
– Trial conducted in India.
– TRS deﬁnition was incomplete.
– Industry sponsored.
Wirshing et al., 1999
(4)
n = 67
8 weeks
PP
Risperidone (7,5)/haloperidol (19) 32%/14% 85%/87% −10/−12 – No differences in efﬁcacy.
– Mix TRS and intolerant patients.
– Industry sponsored
Conley et al., 1998 (5) n = 84
8 weeks
ITT and CA
Inpatients
Olanzapine (25)/chlorpromazine
(1173) + BZT
7%/0% 71%/69% −1/+2 – No differences in efﬁcacy.
– No industry sponsored.
SGA vs SGA
Meltzer et al., 2014 (6) n = 160
24 weeks
RLAI 50/RLAI 100 (biweekly) 45%/45% 72%/70% −18/−18 – No signiﬁcant differences in efﬁcacy.
– Mix TRS patients and poor responders.
– Mix SAD and SCZ.
– Industry sponsored.
Kane et al., 2011 (7) n = 321
12 weeks
ITT
Risperidone (9)/sertindole (18) 58%/45% 71%/68% −21/−19 – Risperidone had more responders.
– Modiﬁed version of PANSS.
– Lax TRS criteria, unclear selection of
participants.
– Industry sponsored.
Clozapine vs FGA
Kane et al., 2001 (8) n = 71
6 months
ITT
In- and
outpatient
Clozapine (520)/haloperidol (19)
+ BZT
57%/25% 65%/33% −10/−5 – Clozapine had more efﬁcacy.
– Favorable discontinuation rate in clozapine.
– Lax response deﬁnition.
– Industry sponsored.
Hong et al., 1997 (9) n = 40
12 weeks
CA
Inpatients
Clozapine (543)/chlorpromazine
(1163)
29%/0% 90%/89% −8/−1 – Clozapine had more efﬁcacy.
– Conducted in China.
– No industry sponsored.
Rosenheck et al., 1997
(10)
n = 423
1 year
ITT
Inpatients
Clozapine (552)/haloperidol
(28) + BZT
37%/32% 57%/28% −12/−8 – No differences in response rate, but favorable
discontinuation rate and total improvement in
clozapine.
– No industry sponsored.
Kane et al., 1988 (11) n = 268
6 weeks
ITT
Inpatients
Clozapine (450)/chlorpromazine
(900) + BZT
30%/4% 88%/87% −16/−5 – Clozapine had more efﬁcacy.
– Industry sponsored.
Clozapine vs SGA
Sacchetti et al., 2010
(12)
n = 147
18 weeks
ITT
Clozapine (365)/ziprasidone (137) 55%/68% 62%/62% −24.5/−25 – Non-inferiority of ziprasidone.
– No differences in EPS.
– Mix TRS patients and intolerants.
– Non-inferiority trial.
– Industry sponsored.
Meltzer et al., 2008 (13) n = 40
24 weeks
PP
Outpatients
Clozapine (564)/olanzapine (34) 60%/50% 48%/74% −20/−21 – No differences in efﬁcacy.
– Mix SAD and SCZ.
– High-doses of olanzapine were used.
– Industry sponsored.
Tollefson et al., 2001
(14)
n = 180
18 weeks
PP
In- and
outpatients
Clozapine (304)/olanzapine (20,5) 34%/38% 59%/60% −14/−15 – Non-inferiority of olanzapine.
– Non-inferiority trial.
– Industry sponsored.
Azorin et al., 2001 (15) n = 273
12 weeks
PP
In- and
outpatients
Clozapine (642)/risperidone (9) 48%/43% 72%/74% −23/−18 – No differences in response rate but clozapine
improved more BPRS and CGI.
– Industry sponsored.
(continued on next page)
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Table 1 (continued)
Trial Study
description
Compared drugs (mg/d) Response
rate
Completion
rate
Improvement
of symptoms
from baseline
Commentaries
Bondolﬁ et al., 1998
(16)
n = 86 8 weeks
ITT
Inpatients
Clozapine (300)/Risperidone (6) 65%/67% 79%/79% −23/−27 – No differences in efﬁcacy.
– Mix TRS patients and intolerants.
– Industry sponsored.
ITT intention to treat analysis, PP per-protocol analysis, CA completers analysis, BZT benzotropine, SAD schizoaffective disorder, SCZ schizophrenia patients, EPS extra-pyramidal symp-
toms, TRS treatment-resistant schizophrenia, FGA ﬁrst-generation antipsychotics, SGA second-generation antipsychotics, RLAI risperidone long-acting injection, NR not reported.
(1) Lal S, Thavundayil JX, Nair NP, Annable L, Ng Ying Kin NM, Gabriel A, Schwartz G. Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind ran-
domized trial. J Psychiatry Neurosci. 2006 Jul;31(4):271–9.
(2) Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R; Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, ran-
domized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007 Feb;68(2):213–23.
(3) Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efﬁcacy and tolerability of ziprasidone in patientswith treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2006 Jan;21(1):21–8.
(4) Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry. 1999 Sep;156(9):1374–9.
(5) ConleyRR, Tamminga CA, Bartko JJ, RichardsonC, PeszkeM, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S. Olanzapine comparedwith chlorpromazine in treatment-resistant schizo-
phrenia. Am J Psychiatry. 1998 Jul;155(7):914–20.
(6) Meltzer HY, Lindenmayer JP, Kwentus J, Share DB, Johnson R, Jayathilake K. A six month randomized controlled trial of long acting injectable risperidone 50 and 100 mg in treatment
resistant schizophrenia. Schizophr Res. 2014 Apr;154(1–3):14–22.
(7) Kane JM, Potkin SG, Daniel DG, Buckley PF. A double-blind, randomized study comparing the efﬁcacy and safety of sertindole and risperidone in patients with treatment-resistant
schizophrenia. J Clin Psychiatry. 2011 Feb;72(2):194–204.
(8) Kane JM, Marder SR, Schooler NR,WirshingWC, Umbricht D, Baker RW,Wirshing DA, Safferman A, Ganguli R, McMenimanM, Borenstein M. Clozapine and haloperidol inmoderately
refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry. 2001 Oct;58(10):965–72.
(9) Hong CJ, Chen JY, Chiu HJ, Sim CB. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin
Psychopharmacol. 1997 May;12(3):123–30.
(10) Rosenheck R, Cramer J, XuW, Thomas J, HendersonW, Frisman L, Fye C, Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia.
Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997 Sep 18;337(12):809–15.
(11) Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988
Sep;45(9):789–96.
(12) Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L; MOZART Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic
treatments: the MOZART study. Schizophr Res. 2009 Aug;113(1):112–21. Erratum in: Schizophr Res. 2010 Aug;121(1–3)281.
(13) Meltzer HY, BoboWV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yağcioğlu AE, Small JG A randomized, double-blind comparison of clozapine and high-dose olanzapine in treat-
ment-resistant patients with schizophrenia. J Clin Psychiatry. 2008 Feb;69(2):274–85.
(14) TollefsonGD, BirkettMA, Kiesler GM,WoodAJ; Lilly Resistant Schizophrenia StudyGroup.Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically
eligible for treatment with clozapine. Biol Psychiatry. 2001 Jan 1;49(1):52–63.
(15) Azorin JM, Spiegel R, Remington G, Vanelle JM, Péré JJ, Giguere M, Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic
schizophrenia. Am J Psychiatry. 2001 Aug;158(8):1305–13.
(16) Bondolﬁ G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study.
The Risperidone Study Group. Am J Psychiatry. 1998 Apr;155(4):499–504.
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smaller number compared to the last meta-analysis (Samara et al.,
2016). Nine compared clozapine versus non-clozapine antipsychotics
and seven compared antipsychotics other than clozapine among
themselves.
Among the seven non-clozapine trials, there were only two well-
designed studies with applicable results:
– Conley et al. (1998): showing no advantage in efﬁcacy of olanzapine
over chlorpromazine at 8 weeks (7% and 0% respectively).
– Lal et al. (2006): showing how high-doses of FGAs produce more
neurological adverse events and they can be difﬁcult to distinguish
from symptoms associatedwith psychosis. The improvement in par-
ticipants' psychopathology could be, at least in part, secondary to
dose reduction.
The other ﬁve trials had many ﬂaws which may lead to erroneous
conclusions (i.e. lax TRS criteria, inclusion of intolerants or
schizoaffective patients, unclear results presentation).
Results showed clozapine superiority over ﬁrst-generation antipsy-
chotics (FGA) in three of four well-designed trials with clear TRS deﬁni-
tions. However, clozapine did not demonstrate superiority over second-
generation antipsychotics (SGA): in our meta-analytic calculation there
was no statistically signiﬁcant advantage for clozapine in terms of re-
sponse (OR 0.94 [95% CI: 0.69–1.27]. The analysis included ﬁve studies,
including in total 339 clozapine and 347 SGA treated patients. There
were no sign of heterogeneity (chi2 = 3.57, I2 = 0.0%, p = 0.47) and
no indication of publication bias (Egger's test, z =−0.24, p = 0.999).
Our results may be true ﬁnding, or be partly explained by 1) unclear el-
igibility criteria (i.e. mixing schizophrenia and schizoaffective patients),2) unclear results presentation, 3) broad TRS deﬁnitionsmixing intoler-
ant patients. In fact, clozapine vs SGA trials achieved higher response
rates compared to clozapine vs FGA trials (see Table 1). Another impor-
tant issue was the lower clozapine doses in clozapine vs SGA trials. Re-
garding this, conclusions of meta-analysis by Samara and colleagues are
very clear: “the underdosing in industry-funded trials could constitute a
serious problem that could have affected the results”. In addition, only
few SGA have been compared with clozapine (i.e. ziprasidone,
olanzapine, risperidone) and therefore, the efﬁcacy in TRS-population
of another SGAs remains unknown (e.g. amisulpride, aripiprazole,
sertindole, quetiapine).
Non-clozapine polypharmacy and high-dose treatment in TRS are
not supported by evidence. To our knowledge there are no studies in
TRS population that compare clozapine monotherapy with non-cloza-
pine polypharmacy, however there are two small open-trials (Kotler
et al., 2004; Suzuki et al., 2008) offering discordant results.
Regarding high-dose treatment, there is only one DBRT (Meltzer et
al., 2008) comparing high-dose of olanzapine (35 mg/d) versus cloza-
pine (550 mg/d), showing similar response rates at 6 months (50%
and 60% respectively). However, this industry supported study exclud-
ed patients who did not respond previously to olanzapine. This reveals
another problem about inclusion of samples with different severity of
treatment-resistance, since the TRS deﬁnition does not state exactly
how effective antipsychotics should have been tried before clozapine.
I.e. the samples with exclusion of patients who had failed trials of
olanzapine may be considered less treatment-resistant than samples
that have included non-responders to, for example, both olanzapine
and risperidone. Underlining this issue, there is NIMH-sponsored
study comparing high-dose of olanzapine (50 mg/d) versus clozapine
(450 mg/d), that we did not include in the revision because it had a
67C. Molins et al. / Schizophrenia Research 178 (2016) 64–67cross-over design and originally was a safety trial, showing better toler-
ability and response rate in clozapine (0% vs 30%) (Conley et al., 2003).
In the review we did not include pragmatic studies because usually
they applied a more liberal deﬁnition of treatment-resistance or they
are not double-blinded (e.g. observational studies, population-based
register studies, cost-effectiveness trials or open-label effectiveness
trials). However, they may provide longitudinal results beyond acute
response, they focus in other important outcomes (e.g. quality of life, so-
cial functions, discontinuation rate) and they also contribute to enhance
our clinical practice. In fact, in many of these studies clozapine was su-
perior to FGA and to SGA (McEvoy et al., 2006).
To summarize, we know surprisingly little about optimal antipsy-
chotic treatment of TRS. However, clozapine remains as the ﬁrst-line
treatment after a failure of two antipsychotic trials according to treat-
ment guidelines (Gaebel et al., 2005; NICE, 2014) and the results of
major pragmatic studies. Varying, and broad deﬁnitions of TRS and
other issues in methodology mentioned earlier in this Letter may
cause problems affecting the interpretation of studies. Indeed, meta-
analyses of original studies with low quality methods lead to ﬂawed
conclusions. Future efforts must ideally focus on 1. well-characterized
TRS samples (e.g. description of symptoms that predominate, onset of
resistance, earlier used antipsychotics), 2. consensus deﬁnition of TRS
to facilitate global interpretation and replication of results (e.g. WHO
has producedwith an expert panel consensus deﬁnition for severe asth-
ma and this is somethingwe need for TRS as well), 3. sample sizes even
above 300 participants “to have power to clearly show a difference of
20% between groups for binary outcomes” (Sinclair and Adams, 2014),
and 4. studies without industry-sponsorship.Role of funding source
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